Novartis Expands Cancer Drugs Portfolio as Kisqali Receives EU Approval
The newest of Novartis’s聽cancer drugs, Kisqali, has received European Union approval. Kisqali will be used as a first-line treatment for…
Global B2B Marketplace for Supplier Selection, Vendor Selection
Global B2B Marketplace for Supplier Selection, Vendor Selection